Kymera Therapeutics, Inc.
KYMR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 14.28 | -0.72 | 1.23 | -1.55 |
| FCF Yield | -0.55% | -1.73% | -3.63% | -1.95% |
| EV / EBITDA | -53.09 | -43.81 | -34.51 | -46.36 |
| Quality | ||||
| ROIC | -8.86% | -8.00% | -8.53% | -8.75% |
| Gross Margin | 0.00% | 81.84% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.33 | 0.78 | 1.21 | 0.87 |
| Growth | ||||
| Revenue 3-Year CAGR | -2.27% | -4.71% | 8.06% | 0.17% |
| Free Cash Flow Growth | 54.95% | 23.91% | -26.94% | -25.44% |
| Safety | ||||
| Net Debt / EBITDA | 0.31 | 3.36 | 0.06 | 0.47 |
| Interest Coverage | 944.09 | -782.94 | -1,033.69 | -1,368.73 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 64.04 | -369.56 | -261.67 |